Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
- 22 December 2009
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 16 (2), 197-207
- https://doi.org/10.1177/1352458509357065
Abstract
In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7—36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose. During months 15—24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg. Of the 250 patients who entered the extension study, 173 (69%) continued to month 36. Most patients were free from gadolinium-enhanced lesions (88—89%) or new T2 lesions (70—78%) at month 36. Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20—0.21, and 68—73% remained relapse-free at month 36. Over 36 months, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events. Pulmonary function remained stable and blood pressure was stable after an initial increase (3—5 mmHg) during the first 6 months of fingolimod treatment; serious adverse events included infections and skin cancer. The low MRI and clinical disease activity at 6 months were maintained at 36 months with fingolimod, which was generally well tolerated by most patients. The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study programme.Keywords
This publication has 16 references indexed in Scilit:
- Oral fingolimod (FTY720) in multiple sclerosisNeurology, 2009
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosisNeurology, 2008
- A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosisBrain, 2008
- Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosisPharmacology & Therapeutics, 2008
- FTY720 modulates human oligodendrocyte progenitor process extension and survivalAnnals of Neurology, 2007
- FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and AustralasiaAmerican Journal of Transplantation, 2006
- Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1Nature, 2004
- Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor AgonistsScience, 2002
- Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted ImagesRadiology, 2000